Status:
UNKNOWN
Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model
Lead Sponsor:
University Medical Center Groningen
Collaborating Sponsors:
Radboud University Medical Center
Conditions:
Ischemia-Reperfusion Injury
Myocardial Infarction
Eligibility:
MALE
18-40 years
Phase:
NA
Brief Summary
Rationale: The investigators hypothesize that EPO protects against apoptosis after acute ischemia in man and that it is detectable using the annexin-A5 model. Objective: Does infusion of a single d...
Eligibility Criteria
Inclusion
- Healthy volunteers between 18 and 40 years of age
- male
- Volunteers are not allowed smoking 24 hours before the start of the experiment
Exclusion
- Female
- Hypertension (SBP \>140 mmHg, DBP \>90 mmHg)
- Diabetes Mellitus (DM) (fasting glc \>6.9 mmol/l, glc \>11.0 mmol/l)
- Hypercholesterolemia
- Renal dysfunction (eGFR \< 60 ml/min, calculated using MDRD formula)
- Any known hypersensitivity/allergic reaction to one of the constituents of Epoetin Alfa
- A history of use of any form of EPO
- Any current medication use
- Cardiovascular disease in medical history
- Smoking less than 24 hours prior to Epoetin alpha infusion
- Participation in research in the last 5 years in which any form of radioactivity was used
- No participation in any research trial in the last 30 days or 5 times the half-life of the used substance
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00691613
Start Date
July 1 2010
End Date
December 1 2011
Last Update
March 12 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Research Centre Nijmegen
Nijmegen, Gelderland, Netherlands, 6500 HB